Astragaloside IV delays vascular aging by enhancing mitochondrial fatty acid β-oxidation via the MLXIPL-PPARα/PGC-1α axis.

Xiangyu Chen, Xiaodie Chen, Nan Xiao, Yutong Yang, Chenghui Li, Yanbin Pan, Huiqun Huang, Xiaodong Duan, Yongan Deng, Chengkai Chen, Shuting Zeng, Simin Yang, Yixuan Huang, Danping Huang, Yubin Yang, Zunpeng Shu, Li Zhang

Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China; Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, Guangdong 519087, China.Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510080, China; Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, Zhuhai, Guangdong 519087, China. · pubmed

Paper

Abstract

Mitochondrial dysfunction and the dysregulation of lipid metabolism are significant contributors to vascular aging, which in turn raises the risk of age-related cardiovascular diseases (CVDs). Buyang Huanwu decoction (BHD), a traditional formula widely used for treating CVDs, has not been thoroughly investigated in terms of its active components and the molecular mechanisms by which it may delay vascular aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Astragaloside IV delays vascular aging by enhancing mitochondrial fatty acid β-oxidation through the MLXIPL-PPARα/PGC-1α axis. This study identifies a specific molecular mechanism for a traditional medicine compound in mitigating vascular aging, representing an incremental advance in understanding the intersection of lipid metabolism and mitochondrial function in age-related vascular decline.

Author of this paper? Send a correction.